Vivos Therapeutics announces trial results in pediatric OSA treatment

Vivos Therapeutics (VVOS) announced first time, peer-reviewed published data confirming that the Vivos DNA is both safe and efficacious in treating children suffering from obstructive sleep apnea, OSA. Results from a multicenter clinical trial, now published in the European Journal of Pediatrics, represent a significant milestone in the fight against one of the most underdiagnosed and undertreated pediatric health conditions. The DNA appliance is part of Vivos’ Complete Airway Repositioning and Expansion line of devices. “We believe this data signals a new era in pediatric OSA treatment,” said Kirk Huntsman, Chairman and CEO of Vivos Therapeutics. “For over a century, surgery has been the go-to treatment for children with OSA. With these results, parents and providers now have strong evidence supporting our DNA appliance as a safe, non-surgical alternative. No child should face invasive surgery without first considering our FDA cleared appliance available through Vivos-trained healthcare providers.”